Phase II Pivotal trial in relapsed HL All ASCT failures Toxicity > Gr 3: ANC 20%, sensory neuropathy 8% thrombocytopenia 6% Individual Patients (n=98)
{"Image DocumentName": "Phase II Pivotal trial in relapsed HL All ASCT failures", "Image ImageDescription": "Med age 31 y, 71% refractory to front line, 66% prior RT. 94% (96 of 102) of patients achieved tumor reduction. ORR 75% (32% CR) Tumor Size (% Change from Baseline) Individual Patients (n=98)  Toxicity > Gr 3: ANC 20% , sensory neuropathy 8% thrombocytopenia 6% Younes et al JCO", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}